microbiome

Developing a range of products to modify the human
microbiome and bring specific health benefits

RNS & Investor News

LPLDL® Non-Exclusive European License Agreement

09 May 2017

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to grant a non-exclusive license agreement to Nutrilinea for the production and commercialisation of products containing OptiBiotix's LPLDL® strain in Europe with a view to maximising the financial return for both parties.

Nutrilinea has over 15 years' experience in the design and development of customised formulations and presentations (capsules, tablets, sachets) for the supplement and pharmaceutical industry. Nutrilinea provides products to both national and international businesses in Europe and the USA, and is one of Europe's fastest growing providers of food supplements, doubling revenues in the last 12 months to over €30m per annum.

Nutrilinea is based in Italy and has established an international reputation for providing innovative product formulations and presentations for different markets, including products containing some of the world's best selling probiotic strains. Nutrilinea intends to produce proprietary formulations containing OptiBiotix's LPLDL® strain developed to reduce cholesterol levels and blood pressure (CholBiome™), and cardiovascular risk (CardioBiome™). Under the terms of the agreement, Nutrilinea intends to produce, promote, market and commercialise OptiBiotix's CholBiome™ and CardioBiome™ products to their European network with the aim of maximising the financial return for both parties.

This pre-launch agreement is another step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's expertise and market reach to serve multiple consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this non-exclusive license agreement with Nutrilinea for the production and commercialisation of products containing OptiBiotix's LPLDL® strain for the reduction of cholesterol and cardiovascular risk. We chose Nutrilinea due to its industry reputation, extensive European network, and record of doubling revenues in the last 12 months. We believe working with Nutrilinea, and similar partners around the world, provide the best opportunity of building LPLDL® into a global brand. We see this as another step in building revenues and market presence of LPLDL® as the 'Intel' inside a wide range of products, provided in different presentations and formulations, for cardiovascular health across both consumer and pharmaceutical markets around the world."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
   
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0883
Liam Murray / Jo Turner  
   
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)  
Tony Quirke (Corporate Broking)  
   
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

back to RNS & Investor News

 

Latest Tweets Twitter

top